Compare DOUG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOUG | AGEN |
|---|---|---|
| Founded | 1911 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 147.4M |
| IPO Year | 2021 | 1999 |
| Metric | DOUG | AGEN |
|---|---|---|
| Price | $1.74 | $3.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 339.8K | ★ 596.6K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | 100.00 |
| EPS | N/A | ★ 1.02 |
| Revenue | ★ $955,578,000.00 | $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.98 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $1.53 | $2.71 |
| 52 Week High | $3.19 | $7.34 |
| Indicator | DOUG | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 44.00 |
| Support Level | $1.69 | $2.93 |
| Resistance Level | $1.86 | $3.15 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 44.83 | 38.70 |
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.